Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

ClinicalTrials.gov ID: NCT05191706

Public ClinicalTrials.gov record NCT05191706. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

Study identification

NCT ID: NCT05191706
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Enrollment: 60 participants

Conditions and interventions

Conditions

Cataract

Interventions

Dexamethasone Drug
Prednisolone Acetate Ophthalmic Drug

Drug

Eligibility (public fields only)

Age range: Up to 3 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 3, 2022
Primary completion: Dec 31, 2025
Completion: Jan 31, 2026
Last update posted: Apr 2, 2025

2022 – 2026

United States locations

U.S. sites: 9
U.S. states: 6
U.S. cities: 9

Facility	City	State	ZIP	Site status
EyePoint Investigational Site	Huntington Beach	California	92647	Recruiting
EyePoint Investigational Site	Palo Alto	California	94303	Active, not recruiting
EyePoint Investigative Site	Boston	Massachusetts	02118	Recruiting
EyePoint Investigational Site	Jackson	Mississippi	39216	Recruiting
EyePoint Investigational Site	Omaha	Nebraska	68114	Recruiting
EyePoint Investigational Site	Buffalo	New York	14209	Recruiting
EyePoint Investigative Site	New York	New York	10032	Recruiting
EyePoint Investigational Site	Rochester	New York	14642	Recruiting
EyePoint Investigational Site	Charleston	South Carolina	29425	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05191706, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 2, 2025 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05191706 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →